Production (Stage)
Galera Therapeutics, Inc.
GRTX
$0.0326
$0.005118.55%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.78M | 11.00M | 11.29M | 12.85M | 19.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.54M | 14.15M | 17.71M | 25.05M | 37.65M |
| Operating Income | -11.54M | -14.15M | -17.71M | -25.05M | -37.65M |
| Income Before Tax | -16.37M | -19.16M | -19.82M | -29.11M | -45.75M |
| Income Tax Expenses | -203.00K | -203.00K | -203.00K | -- | -- |
| Earnings from Continuing Operations | -16.17 | -18.96 | -19.61 | -29.11 | -45.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.17M | -18.96M | -19.61M | -29.11M | -45.75M |
| EBIT | -11.54M | -14.15M | -17.71M | -25.05M | -37.65M |
| EBITDA | -11.52M | -14.13M | -17.47M | -24.81M | -37.40M |
| EPS Basic | -0.28 | -0.35 | -0.36 | -0.59 | -1.00 |
| Normalized Basic EPS | -0.11 | -0.15 | -0.20 | -0.34 | -0.59 |
| EPS Diluted | -0.28 | -0.35 | -0.36 | -0.59 | -1.00 |
| Normalized Diluted EPS | -0.11 | -0.15 | -0.20 | -0.34 | -0.59 |
| Average Basic Shares Outstanding | 262.64M | 218.53M | 217.56M | 208.65M | 197.17M |
| Average Diluted Shares Outstanding | 262.64M | 218.53M | 217.56M | 208.65M | 197.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |